Phase 1Not yet recruiting
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Influence of HDM1005 on Gastric Emptying and Drug-Drug Interaction of HDM1005 and Metformin, Atorvastatin, Warfarin, and Digoxin in Overweight/Obese Adult Chinese Subjects
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 42 planned
- Conditions
- Overweight; Obesity
- Interventions
- Acetaminophen; Metformin; Warfarin; Atorvastatin; Digoxin; HDM1005 injection
- Ages
- adults
- Registry
- NCT07502001
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
Primary outcomes
- Area Under the Concentration Time Curve From Time Zero to ∞ [ AUC(0- ∞)]
- Maximum observed concentration (Cmax)
- Area Under the Concentration Time Curve From Time Zero to t [ AUC(0- t)]
- Time of maximum observed concentration (Tmax)
History
Study completion expected
Primary completion expected
Started
Registered